Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Dose-Escalation, Multiple Dose Study of the Safety, Tolerability, and Immune Response of CRS-207 in Adult Subjects With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment

NCT00585845 is registered in ClinicalTrials.gov with Anza Therapeutics, Inc. as lead sponsor.

NCT NCT00585845
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00585845 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Dose-Escalation, Multiple Dose Study of the Safety, Tolerability, and Immune Response of CRS-207 in Adult Subjects With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment
Lead sponsor
Anza Therapeutics, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
December 31, 2007
Completion date
February 28, 2009
Enrollment
17 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of the ovaries, adenocarcinoma of the pancreas, carcinoma, non-small-cell lung, malignant epithelial mesothelioma